Binder Gwendolyn 4

What Happened
Gwendolyn Binder, President, Science & Technology at Cabaletta Bio (CABA), was granted a derivative award covering 225,000 shares on 2026-03-02. The Form 4 reports an acquisition price of $0 (typical for option or RSU grants); the reported dollar value is $0 on the filing date. This is a grant/award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-03-02; filing date: 2026-03-02 (appears timely).
• Transaction type: Award/Grant of derivative securities (Form 4 code A).
• Shares involved: 225,000 underlying shares. Reported acquisition price: $0; reported total value: $0.
• Vesting: 25% vests on March 1, 2027; remaining 75% vests in 12 substantially equal quarterly installments thereafter, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context
This was a grant of derivative awards (likely stock options or RSUs) rather than a market purchase or sale. Such awards are common for executives and typically vest over several years to align incentives with company performance and retention; they do not by themselves indicate immediate buying or selling activity.